Where is BioPact located?

BioPact is headquartered in Austin, United States. It is registered at 13477 Fitzhugh Road, Austin, TX.

Who is the current CEO of BioPact?

Kurt Swogger of BioPact. They have also founded 1 company.

How many employees does BioPact have?

As of Apr 30, 2026, the latest employee count at BioPact is 3.

Where does BioPact rank among its competitors?

BioPact ranks 2774th amongst 2731 active competitors, of which 709 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of BioPact?

BioPact's top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

BioPact - 2026 Company Profile, Team, Funding & Competitors

BioPact is a funded company based in Austin (United States), founded in 2014 by Kent Phelps and Randy Kinsel. It operates as a Nanoscale biomaterials company enabling intracellular delivery for medical and agricultural solutions. The company has 2731 active competitors, including 709 funded and 465 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Forge Biologics.

Company Details

Nanoscale biomaterials company enabling intracellular delivery for medical and agricultural solutions. They are a B2B tech company focused on breaking barriers in intracellular transport of biomolecules. Their patented technology, MGMR, is a versatile trans-membrane delivery vehicle offering targeted intracellular transport that protects molecular cargo and preserves cellular viability. MGMR's tunable surface chemistry is tailored for loading diverse types of molecular cargo, overcoming specific challenges in molecular delivery and empowering new applications in agriculture, biomanufacturing, therapeutics, and cellular engineering. They provide efficient, controllable intracellular delivery of genetic materials, oligonucleotides, peptides, proteins, and other molecular cargos. They offer solutions for cellular engineering, therapeutic, biomanufacturing and agricultural technologies.

Website: bio-pact.com
Social
Email ID: *****@bio-pact.com
Registered Address: 13477 Fitzhugh Road, Austin, TX

Key Metrics

Founded Year

2014

Location

Austin, United States

Stage

Funding Raised

Investors

Massachusetts Biomedical Initiatives

Ranked

2774^th among 3654 competitors

Employee Count

3 as on Apr 30, 2026

Similar Companies

Alnylam & 3650 more

View BioPact's full profile

BioPact is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
BioPact Cellular Transport, Inc. CIN: 0001797565 , United States, Active		-	2 (As on Dec 31, 2023)	-

BioPact is a funded company. BioPact has 1 institutional investor.

View details of BioPact's funding rounds and investors

The founders of BioPact are Kent Phelps and Randy Kinsel. Kurt Swogger is the CEO of BioPact.

Here are the details of BioPact's key team members:

Kent Phelps: Co-Founder & ex-CEO of BioPact.
Randy Kinsel: Co-Founder & Chairman of BioPact.
Kurt Swogger: Co-Founder & CEO of BioPact.
Contact Info: 1 email address

View details of BioPact's Founder profiles and Board Members

BioPact's employee count trend

BioPact has 3 employees as of Apr 26. Here is BioPact's employee count trend over the years:

Uncover BioPact's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioPact include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of BioPact, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
6th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	69/100
9th	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
2774th	BioPact 2014, Austin (United States), Funding Raised	Nanoscale biomaterials company enabling intracellular delivery for medical and agricultural solutions	-	Massachusetts Biomedical Initiatives	18/100